Global Blood Therapeutics, Inc. (NASDAQ:GBT) Files An 8-K Other Events
Item 8.01. Other Events.
On November 28, 2016, Global Blood Therapeutics, Inc. issued a
press release titled, Global Blood Therapeutics Announces
Initiation of Phase 2a Trial of GBT440 in Idiopathic Pulmonary
Fibrosis (IPF) (the Press Release). A copy of the Press Release
is filed herewith as Exhibit 99.1 and is incorporated herein by
reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
| 99.1 | Press Release, dated November 28, 2016 |
About Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company’s segment is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. It is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is evaluating GBT440 in SCD subjects in an ongoing Phase I/II clinical trial. SCD is a genetic disease marked by red blood cell (RBC) destruction and occluded blood flow and hypoxia, leading to anemia, stroke, multi-organ failure, severe pain crises, and shortened patient life span. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. It is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). Global Blood Therapeutics, Inc. (NASDAQ:GBT) Recent Trading Information
Global Blood Therapeutics, Inc. (NASDAQ:GBT) closed its last trading session 00.00 at 18.55 with 175,562 shares trading hands.
